Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials

被引：0
|
作者：
R Iacovelli
A Altavilla
G Procopio
S Bracarda
M Santoni
S Cascinu
E Cortesi
机构：
[1] Oncology and Human Pathology,Department of Radiology
[2] Oncology Unit B,Department of Medical Oncology
[3] Sapienza University of Rome,undefined
[4] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined
[5] Medical Oncology Unit 1,undefined
[6] Azienda Sanitaria USL 8,undefined
[7] Medical Oncology Unit,undefined
[8] Polytechnic University of the Marche Region,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
castration-resistant prostate cancer; second line; abiraterone acetate; cabazitaxel; enzalutamide; performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 327
页数：4
相关论文
共 50 条
  • [1] Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials
    Iacovelli, R.
    Altavilla, A.
    Procopio, G.
    Bracarda, S.
    Santoni, M.
    Cascinu, S.
    Cortesi, E.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (04) : 323 - 327
  • [2] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [3] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    Oh, William K.
    Miao, Raymond
    Vekeman, Francis
    Sung, Jennifer
    Cheng, Wendy Y.
    Gauthier-Loiselle, Marjolaine
    Dhawan, Ravinder
    Duh, Mei Sheng
    MEDICAL ONCOLOGY, 2017, 34 (09)
  • [4] Treatment of Metastatic, Castration-Resistant, Docetaxel-Resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-Analysis of Randomized Clinical Trials
    Tassinari, Davide
    Cherubini, Chiara
    Roudnas, Britt
    Tamburini, Emiliano
    Drudi, Fabrizio
    Bianchi, Emanuela
    Fantini, Manuela
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (03) : 226 - 237
  • [5] Economic Evaluations of Cabazitaxel for Treatment of Post-docetaxel Metastatic Castration-resistant Prostate Cancer: Evidence from a Systematic Review
    Shahmirzadi, Nikinaz Ashrafi
    Zaboli, Pardis
    Afzali, Monireh
    Tigabu, Bereket Molla
    Hajimiri, Mirhamed
    Ajami, Arman
    Sepehri, Nima
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2019, 31 (06)
  • [6] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    William K. Oh
    Raymond Miao
    Francis Vekeman
    Jennifer Sung
    Wendy Y. Cheng
    Marjolaine Gauthier-Loiselle
    Ravinder Dhawan
    Mei Sheng Duh
    Medical Oncology, 2017, 34
  • [7] Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials
    Roviello, Giandomenico
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Gobbi, Angela
    Senti, Chiara
    Bottini, Alberto
    Ravelli, Andrea
    Bonetta, Alberto
    Paganini, Giovanni
    Generali, Daniele
    MEDICINE, 2016, 95 (43)
  • [8] The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis
    Song, Pan
    Huang, Chuiguo
    Wang, Yan
    INTERNATIONAL JOURNAL OF SURGERY, 2018, 56 : 133 - 140
  • [9] Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
    Chen, Junru
    Zhang, Yaowen
    Zhang, Xingming
    Zhao, Jinge
    Ni, Yuchao
    Zhu, Sha
    He, Ben
    Dai, Jindong
    Wang, Zhipeng
    Wang, Zilin
    Liang, Jiayu
    Zhu, Xudong
    Shen, Pengfei
    Zeng, Hao
    Sun, Guangxi
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [10] Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
    Van Praet, Charles
    Rottey, Sylvie
    Van Hende, Fransien
    Pelgrims, Gino
    Demey, Wim
    Van Aelst, Filip
    Wynendaele, Wim
    Gil, Thierry
    Schatteman, Peter
    Filleul, Bertrand
    Schallier, Dennis
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Everaert, Els
    D'Hondt, Lionel
    Werbrouck, Patrick
    Vermeij, Joanna
    Mebis, Jeroen
    Clausse, Marylene
    Rasschaert, Marika
    Van Erps, Joanna
    Verheezen, Jolanda
    Van Haverbeke, Jan
    Goeminne, Jean-Charles
    Lumen, Nicolaas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 254.e7 - 254.e13
12345